The melanocortin system couples a small family of peptides to five receptors with remarkably different physiological roles, which makes it a demanding but productive research area.
Key Takeaways
- Alpha, beta, and gamma melanocyte-stimulating hormone and adrenocorticotropic hormone are all derived from pro-opiomelanocortin and act on five melanocortin receptors.
- The best-known analogue work concerns MC1R-mediated pigmentation, and an afamelanotide implant is used clinically in a specific photoprotection setting.
- Compounds sold for research in this family are frequently discussed outside their approved indications.
Family and receptors
Alpha, beta, and gamma melanocyte-stimulating hormone and adrenocorticotropic hormone are all derived from pro-opiomelanocortin and act on five melanocortin receptors. The same peptide family therefore influences pigmentation, energy balance, and steroidogenesis depending on which receptor is engaged.
Receptor selectivity is the design problem
Because the ligands share a core sequence, achieving receptor selectivity requires deliberate modification. Linear fragments tend to be non-selective, which is why cyclisation and substitution have been central to the field.
For related mechanism work, see calcitonin peptide.
Pigmentation and photoprotection
The best-known analogue work concerns MC1R-mediated pigmentation, and an afamelanotide implant is used clinically in a specific photoprotection setting. This is one of the clearer translational successes in the family.
Sexual function and MC4R
Bremelanotide acts centrally on melanocortin pathways and is approved for a specific sexual dysfunction indication. Separately, MC4R agonists have been developed for obesity, illustrating how receptor divergence creates separate therapeutic programmes.
Research-use caveats
Compounds sold for research in this family are frequently discussed outside their approved indications. Claims should be tied to the specific molecule and indication that was actually studied.
Experimental Conditions and Practical Setup
Receptor selectivity is determined by measuring cyclic AMP responses in cells expressing each receptor subtype separately, rather than by a single functional assay. Because the endogenous peptides act on several receptors, selectivity ratios rather than absolute potency are the meaningful comparison between analogues.
Melanocortin receptors and their distinct roles
| Receptor | Principal association | Design implication |
|---|---|---|
| MC1R | Pigmentation and photoprotection | Selective agonists developed |
| MC2R | Steroidogenesis | ACTH specific |
| MC3R | Energy homeostasis | Less exploited |
| MC4R | Energy balance and sexual function | Separate obesity programmes |
| MC5R | Exocrine function | Least studied |
Practical Notes for the Bench
- Achieve receptor selectivity through cyclisation and substitution.
- Tie claims to the specific molecule and indication studied.
- Remember that one peptide family acts on five receptors with distinct roles.
Frequently Asked Questions
Why is selectivity difficult here?
Because the melanocortin peptides share a core sequence and act on five receptors with very different physiological roles.
Are any analogues approved?
Yes, including an implantable MC1R-directed agent for photoprotection and a centrally acting agent for a sexual dysfunction indication.
How is selectivity achieved?
Mainly through cyclisation and amino acid substitution, since linear fragments tend to be non-selective.
Why is selectivity the central design problem?
Because the ligands share a core sequence and act on five receptors with very different physiological roles, so non-selective activation produces unwanted effects.
Related Reading
- calcitonin peptide
- somatostatin analogues
- ghrelin peptide hormone
- generic peptide development
- peptide HPLC purity testing
References & Further Reading
- Xu Y et al. Melanocortin 5 receptor signaling pathway in health and disease. Cell Mol Life Sci. 2020. PubMed 32248247
- Zhang L et al. Melanocortin-5 receptor and sebogenesis. Eur J Pharmacol. 2011. PubMed 21215742
- Gebrie A et al. The melanocortin receptor signaling system and its role in neuroprotection against neurodegeneration: Therapeutic insights. Ann N Y Acad Sci. 2023. PubMed 37526975
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- FDA guidance documents on peptide drug products
This article summarises published research practice for laboratory professionals. It is not a guide to human use, and no claim of therapeutic benefit is made or implied.
Reviewed by Priya Raghunathan, MSc, Formulation & Stability Science.